Recently, semaphorin 4a (Sema4A) was described as a novel NRP1 ligand critically involved in suppression of anti-tumor responses by mTregs, but additional ligands mediating immune-modulatory effects of NRP1 are not well-defined (39). The gene discussed is SEMA4A; the disease is neoplasm.